{"transactions":[{"id":52567,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2023-09-19T23:52:07.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":849657,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":849657},"source":{"system":"sec-edgar","filing":"0001610717-23-000289","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/318154/000161071723000289/form4.xml","form_type":"4"}},{"id":52566,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"ten_percent_owner":true}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-19T23:52:07.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":32754291,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":32754291},"source":{"system":"sec-edgar","filing":"0001610717-23-000289","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000161071723000289/form4.xml","form_type":"4"}},{"id":52565,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-19T23:52:07.000Z","date":"2023-09-19","kind":"purchase","planned":false,"acquired":true,"shares":1764705,"price":17,"value":29999985.0,"ownership":{"direct":true},"balance_after":35368653,"source":{"system":"sec-edgar","filing":"0001610717-23-000289","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000161071723000289/form4.xml","form_type":"4"}},{"id":52564,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-19T23:52:07.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":33603948,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."}],"balance_after":33603948,"source":{"system":"sec-edgar","filing":"0001610717-23-000289","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000161071723000289/form4.xml","form_type":"4"}},{"id":73420,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2022-01-12T02:33:07.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":3206281,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3206281},"source":{"system":"sec-edgar","filing":"0000899243-22-001666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924322001666/doc4.xml","form_type":"4"}},{"id":73419,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-12T02:33:07.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":3206281,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series A Preferred Stock were converted into shares of the Issuer's common stock on a one-for-2.7732 basis upon the completion of the Issuer's initial public offering"}],"balance_after":3206281,"source":{"system":"sec-edgar","filing":"0000899243-22-001666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924322001666/doc4.xml","form_type":"4"}},{"id":80777,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2021-09-13T23:27:07.000Z","date":"2021-09-10","kind":"purchase","acquired":true,"shares":165529,"price":302.0615,"value":49999938.0335,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to that Share Purchase Agreement, dated as of September 24, 2020, as amended, by and between the Reporting Person and the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the volume weighted average price on the NASDAQ Stock Market LLC of one American Depositary Share (\"ADS\") of the Issuer for the ninety calendar days preceding August 31, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 246,269,426 Ordinary Shares."}],"balance_after":18943802,"source":{"system":"sec-edgar","filing":"0000899243-21-035731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924321035731/doc4.xml","form_type":"4"}},{"id":96543,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-12-19T02:25:01.000Z","date":"2020-12-18","kind":"grant","acquired":true,"shares":25762,"price":260.9465,"value":6722503.733,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average price.  These American Depositary Shares (\"ADSs\") were purchased at prices ranging from $256.72 to $264.92 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 244,117,549 Ordinary Shares."}],"balance_after":18778273,"source":{"system":"sec-edgar","filing":"0000899243-20-034573","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320034573/doc4.xml","form_type":"4"}},{"id":96681,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-12-18T02:18:33.000Z","date":"2020-12-17","kind":"grant","acquired":true,"shares":74624,"price":260.5396,"value":19442507.1104,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is an average price.  These ADSs were purchased at prices ranging from $254.135 to $265.00 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 243,782,643 Ordinary Shares."}],"balance_after":18752511,"source":{"system":"sec-edgar","filing":"0000899243-20-034372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320034372/doc4.xml","form_type":"4"}},{"id":96680,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-12-18T02:18:33.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":85573,"price":248.2612,"value":21244455.6676,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is an average price.  These ADSs were purchased at prices ranging from $241.29 to $250.17 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."}],"balance_after":18677887,"source":{"system":"sec-edgar","filing":"0000899243-20-034372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320034372/doc4.xml","form_type":"4"}},{"id":96679,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-12-18T02:18:33.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":67941,"price":239.3065,"value":16258722.9165,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average price.  These American Depositary Shares (\"ADSs\") were purchased at prices ranging from $232.86 to $241.845 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."}],"balance_after":18592314,"source":{"system":"sec-edgar","filing":"0000899243-20-034372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320034372/doc4.xml","form_type":"4"}},{"id":101592,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-08-25T21:55:45.000Z","date":"2020-08-25","kind":"grant","acquired":true,"shares":59390,"price":248.4859,"value":14757577.601,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average price.  These American Depositary Shares (\"ADSs\") were purchased at prices ranging from $238.13 to $254.57 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 240,816,849 Ordinary Shares."}],"balance_after":18524373,"source":{"system":"sec-edgar","filing":"0000899243-20-023386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320023386/doc4.xml","form_type":"4"}},{"id":101691,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-08-24T21:47:37.000Z","date":"2020-08-24","kind":"grant","acquired":true,"shares":59390,"price":239.0959,"value":14199905.501,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is an average price.  These ADSs were purchased at prices ranging from $235.15 to $242.535 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 240,044,779 Ordinary Shares."}],"balance_after":18464983,"source":{"system":"sec-edgar","filing":"0000899243-20-023319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320023319/doc4.xml","form_type":"4"}},{"id":101690,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-08-24T21:47:37.000Z","date":"2020-08-21","kind":"grant","acquired":true,"shares":64176,"price":230.1797,"value":14772012.4272,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average price.  These American Depositary Shares (\"ADSs\") were purchased at prices ranging from $237.33 to $243.11 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."}],"balance_after":18405593,"source":{"system":"sec-edgar","filing":"0000899243-20-023319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320023319/doc4.xml","form_type":"4"}},{"id":101772,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-08-20T23:28:30.000Z","date":"2020-08-20","kind":"grant","acquired":true,"shares":64176,"price":234.9941,"value":15080981.3616,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is an average price.  These ADSs were purchased at prices ranging from $229.60 to $237.93 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"As each ADS represents 13 Ordinary Shares of the Issuer, the reported securities represent 238,438,421 Ordinary Shares."}],"balance_after":18341417,"source":{"system":"sec-edgar","filing":"0000899243-20-023107","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320023107/doc4.xml","form_type":"4"}},{"id":101771,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-08-20T23:28:30.000Z","date":"2020-08-19","kind":"grant","acquired":true,"shares":64176,"price":234.8768,"value":15073453.5168,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is an average price.  These ADSs were purchased at prices ranging from $231.33 to $237.16 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."}],"balance_after":18277241,"source":{"system":"sec-edgar","filing":"0000899243-20-023107","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320023107/doc4.xml","form_type":"4"}},{"id":101770,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2020-08-20T23:28:30.000Z","date":"2020-08-18","kind":"grant","acquired":true,"shares":40000,"price":230.1797,"value":9207188.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average price.  These American Depositary Shares (\"ADSs\") were purchased at prices ranging from $223.35 to $235.21 per ADS.  Full information regarding the number of ADSs purchased at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer."}],"balance_after":18213065,"source":{"system":"sec-edgar","filing":"0000899243-20-023107","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320023107/doc4.xml","form_type":"4"}},{"id":103212,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2020-07-16T21:18:54.000Z","date":"2020-07-15","kind":"grant","acquired":true,"shares":29614832,"price":14.2308,"value":421442751.2256,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 206,635,013 securities represented by American Depositary Shares, each of which represents 13 Ordinary Shares of the Issuer."}],"balance_after":236249845,"source":{"system":"sec-edgar","filing":"0000899243-20-019383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924320019383/doc4.xml","form_type":"4"}},{"id":127450,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":12112,"kind":"organization","name":"Onyx Therapeutics, Inc.","position":1,"cik":"0001744260","reported_name":"Onyx Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2018-06-26T01:14:02.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":1121384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1121384},"source":{"system":"sec-edgar","filing":"0000899243-18-018026","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924318018026/doc4.xml","form_type":"4"}},{"id":127449,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":12112,"kind":"organization","name":"Onyx Therapeutics, Inc.","position":1,"cik":"0001744260","reported_name":"Onyx Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T01:14:02.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1121384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":1121384,"source":{"system":"sec-edgar","filing":"0000899243-18-018026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924318018026/doc4.xml","form_type":"4"}},{"id":178183,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock Warrants (Right To Buy)","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"other","acquired":false,"shares":13355,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":6.4022,"underlying":"Common Stock","underlying_shares":13355},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178182,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":false,"price":0,"reported_value":279103,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":41823},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178181,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":false,"shares":117361,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":117361},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178180,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":false,"shares":108932,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":108932},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178179,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":false,"price":0,"reported_value":3000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":448767},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178178,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"purchase","acquired":true,"shares":272142,"price":7,"value":1904994.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":541399,"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178177,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"other","acquired":true,"shares":1141,"price":6.4022,"value":7304.9102,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"In accordance with the terms of the Warrant to Purchase Equity Securities, the warrant was net exercised and based on a fair market value of $7.00 per share, a net of 1,141 shares were acquired by Ventures."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":269257,"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178176,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":true,"shares":268116,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":268116,"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178175,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":true,"shares":448767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."}],"balance_after":448767,"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":183480,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":1,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2013-06-05T20:01:48.000Z","date":"2013-06-05","kind":"exercise","acquired":false,"shares":952381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares.  Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":317460},"source":{"system":"sec-edgar","filing":"0001181431-13-032856","document":"rrd380749.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113032856/rrd380749.xml","form_type":"4"}},{"id":183479,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":1,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-06-05T20:01:48.000Z","date":"2013-06-05","kind":"purchase","acquired":true,"shares":16666,"price":15,"value":249990.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares.  Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":334126,"source":{"system":"sec-edgar","filing":"0001181431-13-032856","document":"rrd380749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113032856/rrd380749.xml","form_type":"4"}},{"id":183478,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":1,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-06-05T20:01:48.000Z","date":"2013-06-05","kind":"exercise","acquired":true,"shares":317460,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares.  Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":317460,"source":{"system":"sec-edgar","filing":"0001181431-13-032856","document":"rrd380749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113032856/rrd380749.xml","form_type":"4"}},{"id":194989,"issuer":{"id":12926,"kind":"organization","name":"MICROMET, INC.","symbol":"MITI"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12927,"kind":"organization","name":"Armstrong Acquisition Corp.","position":2,"cik":"0001543400","reported_name":"Armstrong Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2012-03-08T01:41:34.000Z","date":"2012-03-07","kind":"purchase","acquired":true,"shares":11181711,"price":11,"value":122998821.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On March 7, 2012, following the exercise of the Top-Up Option, Purchaser merged with and into Micromet (the \"Merger\") under the short-form merger provisions of the General Corporation Law of the State of Delaware, with Micromet continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Amgen.  At the effective time of the Merger, each Share issued and outstanding immediately prior to the effective time ceased to be issued and outstanding and (other than Shares then owned by Amgen, Micromet or any of their wholly-owned subsidiaries and Shares held by any stockholders who properly demanded appraisal in connection with the Merger) was converted into the right to receive the Offer Price, without interest, less any applicable withholding taxes. At the effective time of the Merger, all outstanding Shares were cancelled and retired and ceased to exist."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On March 7, 2012, following the exercise of the Top-Up Option, Purchaser merged with and into Micromet (the \"Merger\") under the short-form merger provisions of the General Corporation Law of the State of Delaware, with Micromet continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Amgen.  At the effective time of the Merger, each Share issued and outstanding immediately prior to the effective time ceased to be issued and outstanding and (other than Shares then owned by Amgen, Micromet or any of their wholly-owned subsidiaries and Shares held by any stockholders who properly demanded appraisal in connection with the Merger) was converted into the right to receive the Offer Price, without interest, less any applicable withholding taxes. At the effective time of the Merger, all outstanding Shares were cancelled and retired and ceased to exist."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001181431-12-015374","document":"rrd337739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143112015374/rrd337739.xml","form_type":"4"}},{"id":194988,"issuer":{"id":12926,"kind":"organization","name":"MICROMET, INC.","symbol":"MITI"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12927,"kind":"organization","name":"Armstrong Acquisition Corp.","position":2,"cik":"0001543400","reported_name":"Armstrong Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2012-03-08T01:41:34.000Z","date":"2012-03-07","kind":"purchase","acquired":true,"shares":15951220,"price":11,"value":175463420.0,"ownership":{"direct":false,"nature":"By Armstrong Acquisition Corp."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On March 7, 2012, Purchaser exercised its option (the \"Top-Up Option\") to purchase, at the Offer Price, 15,951,220 Shares (the \"Top-Up Shares\") from Micromet.  The Top-Up Shares, when added to the number of Shares owned by the Purchaser immediately prior to the exercise of the Top-Up Option, resulted in Purchaser owning one Share more than 90% of the Shares of Micromet then outstanding."}],"balance_after":100635409,"source":{"system":"sec-edgar","filing":"0001181431-12-015374","document":"rrd337739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143112015374/rrd337739.xml","form_type":"4"}},{"id":194987,"issuer":{"id":12926,"kind":"organization","name":"MICROMET, INC.","symbol":"MITI"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12927,"kind":"organization","name":"Armstrong Acquisition Corp.","position":2,"cik":"0001543400","reported_name":"Armstrong Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2012-03-08T01:41:34.000Z","date":"2012-03-06","kind":"purchase","acquired":true,"shares":2170710,"price":11,"value":23877810.0,"ownership":{"direct":false,"nature":"By Armstrong Acquisition Corp."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 2, 2012, Armstrong Acquisition Corp. (\"Purchaser\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\"), commenced a subsequent offering period of its tender offer (the \"Offer\") to acquire all of the outstanding shares of common stock, par value $0.00004 per share (together with the associated preferred share purchase rights, the \"Shares\") of Micromet, Inc. (\"Micromet\") at a purchase price of $11.00 per Share in cash (the \"Offer Price\"). The subsequent offering period expired at 12:00 midnight, New York City time, at the end of March 6, 2012."},{"field":"shares","element":"transactionShares","label":"F2","text":"Based on the information provided to Amgen by the depositary for the Offer, on March 6, 2012, approximately 1,542,600 Shares subject to guaranteed delivery procedures in the initial offering period, as described in the Offer to Purchase, dated February 2, 2012 (the \"Offer to Purchase\"), had been validly tendered and accepted for payment and approximately 628,110 Shares had been validly tendered and accepted for payment in the subsequent offering period."}],"balance_after":84684189,"source":{"system":"sec-edgar","filing":"0001181431-12-015374","document":"rrd337739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143112015374/rrd337739.xml","form_type":"4"}},{"id":195021,"issuer":{"id":12926,"kind":"organization","name":"MICROMET, INC.","symbol":"MITI"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12927,"kind":"organization","name":"Armstrong Acquisition Corp.","position":2,"cik":"0001543400","reported_name":"Armstrong Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2012-03-07T00:53:00.000Z","date":"2012-03-05","kind":"purchase","acquired":true,"shares":2035994,"price":11,"value":22395934.0,"ownership":{"direct":false,"nature":"By Armstrong Acquisition Corp."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Following the Expiration Date, the Purchaser commenced a subsequent offering period (the \"Subsequent Offer\") to acquire all of the remaining untendered Shares of Micromet.  The Subsequent Offer is scheduled to expire at 12:00 midnight, New York City time, at the end of March 6, 2012.  Shares validly tendered during this Subsequent Offer are accepted immediately for payment and tendering stockholders are paid the Offer Price, upon the same terms and subject to the same conditions as the Initial Offer, as set forth in the Offer to Purchase and the related Letter of Transmittal included as exhibits to the Tender Offer Statement on Schedule TO-T filed by Purchaser and Amgen with the Securities and Exchange Commission on February 2, 2012, except that Shares tendered during the Subsequent Offer may not be withdrawn."},{"field":"shares","element":"transactionShares","label":"F3","text":"Based on the information provided to Amgen by the Depositary on March 5, 2012, approximately 349,177 Shares subject to guaranteed delivery procedures in the Initial Offer, as described in the Offer to Purchase, had been validly tendered and accepted for payment and approximately 1,686,817 Shares had been validly tendered and accepted for payment in the Subsequent Offer."}],"balance_after":82513479,"source":{"system":"sec-edgar","filing":"0001181431-12-014968","document":"rrd337354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143112014968/rrd337354.xml","form_type":"4"}},{"id":195020,"issuer":{"id":12926,"kind":"organization","name":"MICROMET, INC.","symbol":"MITI"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12927,"kind":"organization","name":"Armstrong Acquisition Corp.","position":2,"cik":"0001543400","reported_name":"Armstrong Acquisition Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2012-03-07T00:53:00.000Z","date":"2012-03-02","kind":"purchase","acquired":true,"shares":452388,"price":11,"value":4976268.0,"ownership":{"direct":false,"nature":"By Armstrong Acquisition Corp."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The initial tender offer (the \"Initial Offer\") commenced by Armstrong Acquisition Corp. (\"Purchaser\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\"), to acquire all of the outstanding shares of common stock, par value $0.00004 per share (together with the associated preferred share purchase rights, the \"Shares\") of Micromet, Inc. (\"Micromet\") at a purchase price of $11.00 per Share in cash (the \"Offer Price\") expired at 12:00 midnight, New York City time, at the end of Thursday, March 1, 2012 (the \"Expiration Date\").  Based on the information provided to Amgen by the depositary for the tender offers (the \"Depositary\") on March 2, 2012, approximately 452,388 Shares subject to guaranteed delivery procedures in the Initial Offer, as described in the Offer to Purchase, dated February 2, 2012 (the \"Offer to Purchase\"), had been validly tendered and accepted for payment."}],"balance_after":80477485,"source":{"system":"sec-edgar","filing":"0001181431-12-014968","document":"rrd337354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143112014968/rrd337354.xml","form_type":"4"}},{"id":298319,"issuer":{"id":14141,"kind":"organization","name":"TULARIK INC","symbol":"TLRK"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2003-11-17T17:29:48.000Z","date":"2003-11-14","kind":"purchase","acquired":true,"shares":1452885,"price":11.9,"value":17289331.5,"ownership":{"direct":true},"balance_after":13952885,"source":{"system":"sec-edgar","filing":"0001181431-03-031206","document":"rrd22904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143103031206/rrd22904.xml","form_type":"4"}},{"id":304101,"issuer":{"id":14141,"kind":"organization","name":"TULARIK INC","symbol":"TLRK"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2003-07-08T22:41:55.000Z","date":"2003-07-08","kind":"purchase","acquired":true,"shares":3000000,"price":7.5,"value":22500000.0,"ownership":{"direct":true},"balance_after":12500000,"source":{"system":"sec-edgar","filing":"0001181431-03-013398","document":"rrd12642.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143103013398/rrd12642.xml","form_type":"4"}},{"id":304067,"issuer":{"id":14141,"kind":"organization","name":"TULARIK INC","symbol":"TLRK"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2003-07-01T20:42:10.000Z","date":"2003-06-27","kind":"purchase","acquired":true,"shares":3500000,"price":10,"value":35000000.0,"ownership":{"direct":true},"balance_after":9500000,"source":{"system":"sec-edgar","filing":"0001181431-03-012412","document":"rrd11544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143103012412/rrd11544.xml","form_type":"4"}},{"id":305099,"issuer":{"id":14141,"kind":"organization","name":"TULARIK INC","symbol":"TLRK"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2003-06-02T19:52:06.000Z","kind":"other","shares":6000000,"ownership":{"direct":true},"source":{"system":"sec-edgar","filing":"0001181431-03-009586","document":"rrd9866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143103009586/rrd9866.xml","form_type":"3"}}]}